Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

A limited number of secondary baseline variables showed modest between‐group differences, including vitamin D supplementation, brain‐derived neurotrophic factor, procollagen type III N‐terminal peptide, tumour necrosis factor alpha and T12‐L4 VFI.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This prospective observational cohort study included 186 postmenopausal women with osteoporosis and prescreened sarcopenia risk (82 denosumab, 104 zoledronic acid).

Source: Abstract.

Between March 2020 and April 2022, we prospectively screened 311 consecutive postmenopausal women aged 50 years or older with confirmed osteoporosis who initiated denosumab or zoledronic acid.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Denosumab Versus Zoledronic Acid for Muscle Strength and Physical Performance in Postmenopausal Osteoporosis: A 3‐Year Prospective Study

Cohort study · Journal of Cachexia, Sarcopenia and Muscle · 2026

Original publication title

Denosumab Versus Zoledronic Acid for Muscle Strength and Physical Performance in Postmenopausal Osteoporosis: A 3‐Year Prospective Study

Xiangwen Li; Zineng Yuan; Nina Ma; Bijuan Huang; Hongyue Tao; Shuang Chen

© 2026 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Compared with zoledronic acid, denosumab was associated with stronger early OPG/sRANKL activation, earlier functional improvement, more favourable CT‐defined remodelling, later DXA‐derived muscle‐mass gain and lower study‐defined sarcopenia burden based on an AWGS 2025‐informed framework over 3 years. These findings support validation of RANKL inhibition in osteosarcopenic phenotypes.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Osteoporosis and sarcopenia frequently coexist in older adults, yet whether denosumab provides muscle‐related benefits beyond bone remains uncertain. We compared denosumab and zoledronic acid across functional, imaging, biologic and study‐defined sarcopenia outcomes based on an Asian Working Group for Sarcopenia (AWGS) 2025‐informed framework and examined whether early osteoprotegerin (OPG)/soluble receptor activator of nuclear factor‐kappa B ligand (sRANKL) responses tracked with later benefit.

Source: Background

Abstract: What methods does the paper describe?

This prospective observational cohort study included 186 postmenopausal women with osteoporosis and prescreened sarcopenia risk (82 denosumab, 104 zoledronic acid). Assessments at baseline and 12, 24 and 36 months included grip strength, gait speed, 5‐times chair stand, lumbar spine and femoral neck bone mineral density (BMD), dual‐energy X‐ray absorptiometry (DXA)‐derived appendicular skeletal muscle mass index (ASMI), computed tomography (CT)‐derived T12‐L4 skeletal muscle volume index (SMVI), skeletal muscle density (SMD), intermuscular fat volume index (IMFI), visceral fat volume index (VFI) and OPG/sRANKL‐centred biologic markers.

Continuous outcomes were analysed using linear mixed‐effects models, categorical outcomes with Fisher exact tests and responder and mediation analyses.

Source: Methods

Abstract: Results

Denosumab showed greater functional improvement than zoledronic acid. At 12 months, grip strength increased by 1.45 ± 0.51 versus 0.66 ± 0.34 kg, gait speed by 0.041 ± 0.013 versus 0.017 ± 0.011 m/s and 5‐times chair stand time by −0.82 ± 0.27 versus −0.32 ± 0.18 s (all p < 0.001). At 36 months, changes were 2.52 ± 0.63 versus 0.99 ± 0.45 kg, 0.070 ± 0.017 versus 0.027 ± 0.012 m/s and −1.47 s (−1.63, −1.34) versus −0.63 s (−0.82, −0.50) (all p < 0.001).

ASMI did not differ at 12 months (p = 0.119) but favoured denosumab at 24 and 36 months (both p < 0.001; 36‐month change, 0.192 ± 0.059 vs. 0.089 ± 0.050 kg/m2). Sarcopenia prevalence was lower with denosumab at 12, 24 and 36 months (52.1% vs. 69.8%, 30.2% vs. 50.7% and 20.0% vs. 46.0%), and remission was higher (36.7% vs. 15.5%, 63.5% vs. 37.3% and 75.0% vs. 37.0%). Denosumab also produced greater increases in SMVI and SMD and greater reductions in IMFI and VFI.

The OPG/sRANKL ratio increased more strongly at 12 months (2.503 [2.053, 3.429] vs. 0.807 [0.549, 0.994], p < 0.001). High responders had larger 36‐month gains in grip strength (2.80 ± 0.65 vs. 2.21 ± 0.44 kg, p < 0.001) and CT‐defined SMVI (2.816 ± 0.861 vs. 2.199 ± 0.524, p = 0.002). Twelve‐month OPG/sRANKL change showed a pattern statistically consistent with partial mediation of the association between treatment group and 36‐month grip strength (37.0%) and CT‐defined SMVI (39.9%).

Source: Results

Abstract: Conclusions

Compared with zoledronic acid, denosumab was associated with stronger early OPG/sRANKL activation, earlier functional improvement, more favourable CT‐defined remodelling, later DXA‐derived muscle‐mass gain and lower study‐defined sarcopenia burden based on an AWGS 2025‐informed framework over 3 years. These findings support validation of RANKL inhibition in osteosarcopenic phenotypes.

Source: Conclusions
Authors’ abstract

ABSTRACT

Background

Osteoporosis and sarcopenia frequently coexist in older adults, yet whether denosumab provides muscle‐related benefits beyond bone remains uncertain. We compared denosumab and zoledronic acid across functional, imaging, biologic and study‐defined sarcopenia outcomes based on an Asian Working Group for Sarcopenia (AWGS) 2025‐informed framework and examined whether early osteoprotegerin (OPG)/soluble receptor activator of nuclear factor‐kappa B ligand (sRANKL) responses tracked with later benefit.

Methods

This prospective observational cohort study included 186 postmenopausal women with osteoporosis and prescreened sarcopenia risk (82 denosumab, 104 zoledronic acid). Assessments at baseline and 12, 24 and 36 months included grip strength, gait speed, 5‐times chair stand, lumbar spine and femoral neck bone mineral density (BMD), dual‐energy X‐ray absorptiometry (DXA)‐derived appendicular skeletal muscle mass index (ASMI), computed tomography (CT)‐derived T12‐L4 skeletal muscle volume index (SMVI), skeletal muscle density (SMD), intermuscular fat volume index (IMFI), visceral fat volume index (VFI) and OPG/sRANKL‐centred biologic markers.

Continuous outcomes were analysed using linear mixed‐effects models, categorical outcomes with Fisher exact tests and responder and mediation analyses.

Results

Denosumab showed greater functional improvement than zoledronic acid. At 12 months, grip strength increased by 1.45 ± 0.51 versus 0.66 ± 0.34 kg, gait speed by 0.041 ± 0.013 versus 0.017 ± 0.011 m/s and 5‐times chair stand time by −0.82 ± 0.27 versus −0.32 ± 0.18 s (all p < 0.001). At 36 months, changes were 2.52 ± 0.63 versus 0.99 ± 0.45 kg, 0.070 ± 0.017 versus 0.027 ± 0.012 m/s and −1.47 s (−1.63, −1.34) versus −0.63 s (−0.82, −0.50) (all p < 0.001).

ASMI did not differ at 12 months (p = 0.119) but favoured denosumab at 24 and 36 months (both p < 0.001; 36‐month change, 0.192 ± 0.059 vs. 0.089 ± 0.050 kg/m2). Sarcopenia prevalence was lower with denosumab at 12, 24 and 36 months (52.1% vs. 69.8%, 30.2% vs. 50.7% and 20.0% vs. 46.0%), and remission was higher (36.7% vs. 15.5%, 63.5% vs. 37.3% and 75.0% vs. 37.0%). Denosumab also produced greater increases in SMVI and SMD and greater reductions in IMFI and VFI.

The OPG/sRANKL ratio increased more strongly at 12 months (2.503 [2.053, 3.429] vs. 0.807 [0.549, 0.994], p < 0.001). High responders had larger 36‐month gains in grip strength (2.80 ± 0.65 vs. 2.21 ± 0.44 kg, p < 0.001) and CT‐defined SMVI (2.816 ± 0.861 vs. 2.199 ± 0.524, p = 0.002). Twelve‐month OPG/sRANKL change showed a pattern statistically consistent with partial mediation of the association between treatment group and 36‐month grip strength (37.0%) and CT‐defined SMVI (39.9%).

Conclusions

Compared with zoledronic acid, denosumab was associated with stronger early OPG/sRANKL activation, earlier functional improvement, more favourable CT‐defined remodelling, later DXA‐derived muscle‐mass gain and lower study‐defined sarcopenia burden based on an AWGS 2025‐informed framework over 3 years. These findings support validation of RANKL inhibition in osteosarcopenic phenotypes.

Publication and source details

Original title: Denosumab Versus Zoledronic Acid for Muscle Strength and Physical Performance in Postmenopausal Osteoporosis: A 3‐Year Prospective Study

Xiangwen Li; Zineng Yuan; Nina Ma; Bijuan Huang; Hongyue Tao; Shuang Chen

Journal of Cachexia, Sarcopenia and Muscle · 2026

* Correspondence:
Shuang Chen (chenshuang6898@126.com)
© 2026 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. National Natural Science Foundation of China10.13039/501100001809 82502296

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:35:44.230774+00:00

DOI: 10.1002/jcsm.70406 · PMC13685528